Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

Michelle Petri, Ian N. Bruce, Thomas Dörner, Yoshiya Tanaka, Eric F. Morand, Kenneth C. Kalunian, Mario H. Cardiel, Maria E. Silk, Christina L. Dickson, Gabriella Meszaros, Lu Zhang, Bochao Jia, Youna Zhao, Conor J. McVeigh, Marta Mosca

School of Clinical Sciences at Monash Health
Centre for Inflammatory Disease Monash Health

Research output: Contribution to journal › Article › Research › peer-review

91 Citations (Scopus)

91 Citations
1 Article

1 results

Filter

2023

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)
Morand, E. F., Vital, E. M., Petri, M., van Vollenhoven, R., Wallace, D. J., Mosca, M., Furie, R. A., Silk, M. E., Dickson, C. L., Meszaros, G., Jia, B., Crowe, B., de la Torre, I. & Dörner, T., 25 Mar 2023, In: The Lancet. 401, 10381, p. 1001-1010 10 p.
Research output: Contribution to journal › Article › Research › peer-review

83 Citations (Scopus)

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

Research output

Search results

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)